ClinicalTrials.gg
CompletedNCT02716610Samba-02Updated Mar 23, 2016

Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes

A Phase 1/2 interventional study of INH 69 U (low) and INH 69 U (high) in Type 2 Diabetes Mellitus, sponsored by Dance Biopharm Inc.. Completed. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2016-03-23.

Sponsored by Dance Biopharm Inc. · Phase 1/2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Study summary

Pharmacokinetic (PK) and Pharmacodynamic (PD) dose-response investigation of Dance-501 inhaled human insulin

Read the detailed description

This study investigated the pharmacokinetic (PK) and pharmacodynamic (PD) properties of Dance-501, a novel inhaled human insulin liquid formulation (INH) and device. Twenty-four subjects with type 2 diabetes (T2DM) received 3 INH doses: low (69 units), medium (139 units) and high (208 units) and 1 equivalent medium dose (18 units) of subcutaneous insulin lispro (LIS).

The medium dose was repeated to determine within subject variability. PD was investigated during a 12 hour euglycemic clamp.

02

Conditions studied

  • Type 2 Diabetes Mellitus
03

In context

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 24 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Dance Biopharm Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus treated with insulin injections at a total daily dose less than 1.2 U/kg/day.
  • 25-40 kg/m2
  • 6.5-9.5%
  • Forced vital capacity and at least 75% of predicted normal values.
  • Fasting c-peptide less than 1 nmol/L

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption from the lung, in particular subjects with decreased lung function or subjects taking bronchodilators or subjects who smoke.
  • Active or chronic pulmonary disease.
  • Any major disorder other than type 2 diabetes.
  • Decompensated heart failure or myocardial infarction at any time or angina pectoris within the last 12 months.
  • Proliferative retinopathy or maculopathy or severe neuropathy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1 / Phase 2
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    INH 69 U (low)

    single 69 U dose administration of Dance inhaled human insulin using a low-concentration formulation (300 U/mL)

    Drug: INH 69 U (low)

  • Experimental
    INH 69 U (high)

    single 69 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)

    Drug: INH 69 U (high)

  • Experimental
    INH 139 U

    single 139 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL) This arm was repeated in order to evaluate intra-subject variability.

    Drug: INH 139 U

  • Experimental
    INH 208 U

    single 208 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)

    Drug: INH 208 U

  • Active comparator
    LIS 18 U

    single 18 U dose administration of subcutaneous insulin lispro using a 100 U/mL formulation This arm was repeated in order to evaluate intra-subject variability.

    Drug: LIS 18 U

Interventions

  • DrugINH 69 U (low)

    inhaled human insulin

    Also known as: Dance-501

  • DrugINH 69 U (high)

    inhaled human insulin

    Also known as: Dance-501

  • DrugINH 139 U

    inhaled human insulin

    Also known as: Dance-501

  • DrugINH 208 U

    inhaled human insulin

    Also known as: Dance-501

  • DrugLIS 18 U

    subcutaneous insulin lispro

    Also known as: subcutaneous insulin lispro

06

What researchers measure

Primary outcomes

  1. Area under the curve for insulin from 0-8 hours (AUCins0-8h)

    Assessment of the linearity of the dose-response curves

    Time frame: 0 to 8 hours following each dose

  2. Maximum concentration of insulin (CMaxIns)

    Assessment of the linearity of the dose-response curves

    Time frame: up to 12 hours following each dose

  3. Area under the curve for glucose infusion rate from 0-12 hours (AUGgir0-12h)

    Assessment of the linearity of the dose-response curves

    Time frame: 0 to 8 hours following each dose

  4. Maximum glucose infusion rate (GIRmax)

    Assessment of the linearity of the dose-response curves

    Time frame: up to 12 hours following each dose

Secondary outcomes

  1. Bioavailability

    Relative delivery efficiency (FREL) of inhaled human insulin (INH) compared to subcutaneous injected insulin lispro (LIS)

    Time frame: 0 to 8 hours following each dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2016
First posted
Mar 23, 2016
Start
Oct 2013
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Last update
Mar 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02716610
Lead sponsor
Dance Biopharm Inc.
Responsible party
Sponsor
First posted
Mar 23, 2016
Start date
Oct 2013
Primary completion
Jan 2014
Completion
Jan 2014
Last update
Mar 23, 2016

Study contacts

Tim Heise, MD
principal investigator · Profil Institut für Stoffwechselforschung GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion